Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

about

Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms Emerging drugs for prostate cancer.

P2860

Q36485297-6780135F-DA3F-4949-A209-CAA530993E52 Q37570555-8A7CD9BE-5DA5-4316-822D-7010DF42B044

P2860

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

Item

http://www.wikidata.org/entity/Q36474196

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

@ast

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

@en

type

Item

label

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

@ast

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

@en

prefLabel

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

@ast

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

@en

P1476

Interfering with cell-survival signalling as a treatment strategy for prostate cancer

@en

P2093

Anthony J Costello

http://www.w3.org/2001/XMLSchema#string

Niall M Corcoran

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.

Coxibs and cardiovascular disease.

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

P304

1149-1153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1111/J.1464-410X.2006.06198.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christopher M Hovens

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16686702

http://www.w3.org/2001/XMLSchema#string

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

about

P2860

P2860

Interfering with cell-survival signalling as a treatment strategy for prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698